Membrane interaction and structure of the transmembrane domain of influenza hemagglutinin and its fusion peptide complex

Institute of Chemistry, Academia Sinica, Taipei, Taiwan 11529, Republic of China.
BMC Biology (Impact Factor: 7.98). 02/2008; 6:2. DOI: 10.1186/1741-7007-6-2
Source: PubMed

ABSTRACT To study the organization and interaction with the fusion domain (or fusion peptide, FP) of the transmembrane domain (TMD) of influenza virus envelope glycoprotein for its role in membrane fusion which is also essential in the cellular trafficking of biomolecules and sperm-egg fusion.
The fluorescence and gel electrophoresis experiments revealed a tight self-assembly of TMD in the model membrane. A weak but non-random interaction between TMD and FP in the membrane was found. In the complex, the central TMD oligomer was packed by FP in an antiparallel fashion. FP insertion into the membrane was altered by binding to TMD. An infrared study exhibited an enhanced membrane perturbation by the complex formation. A model was built to illustrate the role of TMD in the late stages of influenza virus-mediated membrane fusion reaction.
The TMD oligomer anchors the fusion protein in the membrane with minimal destabilization to the membrane. Upon associating with FP, the complex exerts a synergistic effect on the membrane perturbation. This effect is likely to contribute to the complete membrane fusion during the late phase of fusion protein-induced fusion cascade. The results presented in the work characterize the nature of the interaction of TMD with the membrane and TMD in a complex with FP in the steps leading to pore initiation and dilation during virus-induced fusion. Our data and proposed fusion model highlight the key role of TMD-FP interaction and have implications on the fusion reaction mediated by other type I viral fusion proteins. Understanding the molecular mechanism of membrane fusion may assist in the design of anti-viral drugs.

Download full-text


Available from: Yu-Tsan Liu, Jan 22, 2014
1 Follower
  • Source
    • "Following this idea, Chang et al. explored the existence of actual interactions between HA FP and TMD and its involvement in the IFV fusion process (Chang et al., 2008). They used fluorescently labeled peptides and model membranes, to assay formation of complexes between FP and TMD domains. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fusion peptides comprise conserved hydrophobic domains absolutely required for the fusogenic activity of glycoproteins from divergent virus families. After 30 years of intensive research efforts, the structures and functions underlying their high degree of sequence conservation are not fully elucidated. The long-hydrophobic viral fusion peptide (VFP) sequences are structurally constrained to access three successive states after biogenesis. Firstly, the VFP sequence must fulfill the set of native interactions required for (meta)stable folding within the globular ectodomains of glycoprotein complexes. Secondly, at the onset of the fusion process, they get transferred into the target cell membrane and adopt specific conformations therein. According to commonly accepted mechanistic models, membrane-bound states of the VFP might promote the lipid bilayer remodeling required for virus-cell membrane merger. Finally, at least in some instances, several VFPs co-assemble with transmembrane anchors into membrane integral helical bundles, following a locking movement hypothetically coupled to fusion-pore expansion. Here we review different aspects of the three major states of the VFPs, including the functional assistance by other membrane-transferring glycoprotein regions, and discuss briefly their potential as targets for clinical intervention.
    Chemistry and Physics of Lipids 04/2014; 181. DOI:10.1016/j.chemphyslip.2014.03.003 · 2.59 Impact Factor
  • Source
    • "). The active fusion core of viruses such as influenza and the human immunodeficiency virus constitutes a 6-helix bundle consisting of two helices from each fusion protein in the trimer (Skehel and Wiley, 2000; Melikyan et al., 2000; Russel et al., 2001; Chang et al., 2008). Its formation can be prevented by antiviral peptides that mimic the helices and compete with the protein-protein interactions that give rise to the fusion core (Hsieh and Hsu JT., 2007; Stevens and Donis, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: With the emergence and rapid spread of West Nile virus in the United States since 1999, and the 50-100 million infections per year caused by dengue virus globally, the threat of flaviviruses as re-emerging human pathogens has become a reality. To support the efforts that are currently being pursued to develop effective vaccines against these viruses, researchers are also actively pursuing the development of small molecule compounds that target various aspects of the virus life cycle. Recent advances in the structural characterization of the flaviviruses have provided a strong foundation towards these efforts. These studies have provided the pseudo-atomic structures of virions from several members of the genus as well as atomic resolution structures of several viral proteins. Most importantly, these studies have highlighted specific structural rearrangements that occur within the virion that are necessary for the virus to complete its life cycle. These rearrangements occur when the virus must transition from immature, to mature, to fusion-active states and rely heavily on the conformational flexibility of the envelope (E) protein that forms the outer glycoprotein shell of the virus. Analysis of these conformational changes can suggest promising targets for structure-based antiviral design. For instance, by targeting the flexibility of the E protein, it might be possible to inhibit required rearrangements of this protein and trap the virus in a specific state. This would interfere with a productive flaviviral infection. This review presents a structural perspective of the flavivirus life cycle and focuses on the role of the E protein as an opportune target for structure-based antiviral drug design.
    Antiviral Research 07/2008; 80(1):11-22. DOI:10.1016/j.antiviral.2008.05.004 · 3.94 Impact Factor
  • Comprehensive Analytical Chemistry 01/2009; 55:49-76. DOI:10.1016/S0166-526X(09)05503-2
Show more